388 related articles for article (PubMed ID: 12478902)
41. Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0.
Sobrevilla-Calvo P; Zinser Sierra JW; Lara Medina FU; Acosta Barreda A; Calderón Flores E
Rev Invest Clin; 2002; 54(1):51-6. PubMed ID: 11995407
[TBL] [Abstract][Full Text] [Related]
42. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF.
Mitterer M; Hirber J; Gentilini I; Prinoth O; Fabris P; Emmerich B; Coser P; Straka C
Bone Marrow Transplant; 1996 Sep; 18(3):611-7. PubMed ID: 8879626
[TBL] [Abstract][Full Text] [Related]
43. [Mobilization of autologous peripheral blood stem cells by chemotherapy and recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)].
Cui X; Shao Y; Ren B; Tong Z; Ren X; Li L; Zhang Z; Zhang N; Dai R; Hao X
Zhonghua Xue Ye Xue Za Zhi; 2000 May; 21(5):247-9. PubMed ID: 11876989
[TBL] [Abstract][Full Text] [Related]
44. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
[TBL] [Abstract][Full Text] [Related]
45. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
46. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
47. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
[TBL] [Abstract][Full Text] [Related]
48. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
49. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
[TBL] [Abstract][Full Text] [Related]
50. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
51. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
[TBL] [Abstract][Full Text] [Related]
52. Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.
Ke X; Yang Y; Zhao X; Wang L
Chin Med J (Engl); 2001 Feb; 114(2):196-9. PubMed ID: 11780206
[TBL] [Abstract][Full Text] [Related]
53. Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen.
Balduzzi A; Perseghin P; Dassi M; Bonanomi S; Rovelli A; Gaipa G; Biondi A; Uderzo C
Bone Marrow Transplant; 2002 Oct; 30(7):413-6. PubMed ID: 12368951
[TBL] [Abstract][Full Text] [Related]
54. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
55. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
56. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
57. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
[TBL] [Abstract][Full Text] [Related]
58. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
59. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
[TBL] [Abstract][Full Text] [Related]
60. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer.
Charrier S; Chollet P; Bay JO; Curé H; Kwiatkowski F; Portefaix G; Communal Y; Bétail G; Plagne R; Chassagne J
Bone Marrow Transplant; 2000 Apr; 25(7):705-10. PubMed ID: 10745254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
